Lexicon (NASDAQ: LXRX) CFO receives new RSU and stock option grants

Rhea-AI Filing Summary

Lexicon Pharmaceuticals SVP and CFO Scott M. Coiante received new equity awards as part of his compensation. On February 12, 2026, he was granted 272,680 restricted stock units, each representing a contingent right to one share of common stock. These RSUs vest in three equal installments on February 28 of each of the three years after the grant year.

On the same date, he also received 409,020 stock options with an exercise price of $1.37 per share, expiring on February 12, 2036. The option vests 25% on the first anniversary of grant, then in equal monthly installments over the following three years, all held as direct ownership.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Coiante Scott M

Role SVP, Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	272,680	$0.00	--
Grant/Award	Stock Option (Right to Buy)	409,020	$0.00	--

Holdings After Transaction: Restricted Stock Units — 272,680 shares (Direct); Stock Option (Right to Buy) — 409,020 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of common stock. Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coiante Scott M

(Last) (First) (Middle)

2445 TECHNOLOGY FOREST BLVD

11TH FLOOR

(Street)

SPRING TX 77381

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEXICON PHARMACEUTICALS, INC. [ LXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/12/2026		A		272,680		(2)	(2)	Common Stock	272,680	$0	272,680	D
Stock Option (Right to Buy)	$1.37	02/12/2026		A		409,020		(3)	02/12/2036	Common Stock	409,020	$0	409,020	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock.

2. Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.

3. Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.

	/s/ Scott M. Coiante	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Lexicon Pharmaceuticals (LXRX) report for its CFO?

Lexicon Pharmaceuticals reported that SVP and Chief Financial Officer Scott M. Coiante received equity awards. On February 12, 2026 he was granted restricted stock units and stock options as part of his compensation, rather than buying or selling shares in the open market.

How many restricted stock units did the Lexicon (LXRX) CFO receive?

Scott M. Coiante received 272,680 restricted stock units. Each unit represents a contingent right to receive one share of Lexicon common stock. The RSUs vest in three equal installments on February 28 in each of the three years following the year of grant.

What is the vesting schedule for the Lexicon (LXRX) CFO’s RSU grant?

The RSU grant vests over three years. One-third of the 272,680 restricted stock units vests on February 28 of each of the three years following the grant year, aligning the award with continued service over that period.

What stock options were granted to the Lexicon (LXRX) CFO in this Form 4?

Scott M. Coiante was granted 409,020 stock options with an exercise price of $1.37 per share. These options give him the right to buy Lexicon common stock and expire on February 12, 2036, subject to vesting conditions.

How do the Lexicon (LXRX) CFO’s stock options vest over time?

The option vests 25% of the shares on the first anniversary of the February 12, 2026 grant. The remaining 75% then vests in equal monthly installments, 1/48th per month, for each additional month of continued service after that first year.

Are the Lexicon (LXRX) CFO’s new equity awards held directly or indirectly?

The Form 4 shows the equity awards as held in direct ownership. Both the restricted stock units and the stock options are reported with an ownership code of “D,” indicating they are directly owned by Scott M. Coiante rather than through an intermediary entity.